Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513

Watchlist Manager
Chengdu Easton Biopharmaceuticals Co Ltd Logo
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Watchlist
Price: 35.07 CNY -3.55% Market Closed
Market Cap: 6.2B CNY
Have any thoughts about
Chengdu Easton Biopharmaceuticals Co Ltd?
Write Note

Profitability Summary

Chengdu Easton Biopharmaceuticals Co Ltd's profitability score is 54/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

54/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

High Profitability Stocks
Pharmaceuticals Industry

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Chengdu Easton Biopharmaceuticals Co Ltd

Revenue
1.2B CNY
Cost of Revenue
-254.9m CNY
Gross Profit
899.4m CNY
Operating Expenses
-679.3m CNY
Operating Income
220.1m CNY
Other Expenses
20.5m CNY
Net Income
240.6m CNY

Margins Comparison
Chengdu Easton Biopharmaceuticals Co Ltd Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CN
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
6.2B CNY
78%
19%
21%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
761.8B USD
81%
35%
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
85%
44%
35%
US
Johnson & Johnson
NYSE:JNJ
368.4B USD
69%
28%
17%
US
Merck & Co Inc
NYSE:MRK
250.9B USD
77%
34%
19%
CH
Roche Holding AG
SIX:ROG
208.8B CHF
73%
32%
20%
CH
Novartis AG
SIX:NOVN
181.2B CHF
75%
29%
33%
UK
AstraZeneca PLC
LSE:AZN
158.6B GBP
82%
21%
13%
IE
Endo International PLC
LSE:0Y5F
155B USD
68%
11%
-126%
Country CN
Market Cap 6.2B CNY
Gross Margin
78%
Operating Margin
19%
Net Margin
21%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 761.8B USD
Gross Margin
81%
Operating Margin
35%
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Operating Margin
3%
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Gross Margin
85%
Operating Margin
44%
Net Margin
35%
Country US
Market Cap 368.4B USD
Gross Margin
69%
Operating Margin
28%
Net Margin
17%
Country US
Market Cap 250.9B USD
Gross Margin
77%
Operating Margin
34%
Net Margin
19%
Country CH
Market Cap 208.8B CHF
Gross Margin
73%
Operating Margin
32%
Net Margin
20%
Country CH
Market Cap 181.2B CHF
Gross Margin
75%
Operating Margin
29%
Net Margin
33%
Country UK
Market Cap 158.6B GBP
Gross Margin
82%
Operating Margin
21%
Net Margin
13%
Country IE
Market Cap 155B USD
Gross Margin
68%
Operating Margin
11%
Net Margin
-126%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Chengdu Easton Biopharmaceuticals Co Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CN
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
6.2B CNY
10%
8%
9%
13%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
761.8B USD
66%
13%
33%
19%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
89%
27%
75%
35%
US
Johnson & Johnson
NYSE:JNJ
368.4B USD
20%
8%
18%
13%
US
Merck & Co Inc
NYSE:MRK
250.9B USD
28%
11%
25%
20%
CH
Roche Holding AG
SIX:ROG
208.8B CHF
40%
13%
29%
22%
CH
Novartis AG
SIX:NOVN
181.2B CHF
35%
16%
20%
15%
UK
AstraZeneca PLC
LSE:AZN
158.6B GBP
17%
6%
14%
12%
IE
Endo International PLC
LSE:0Y5F
155B USD
70%
-51%
5%
6%
Country CN
Market Cap 6.2B CNY
ROE
10%
ROA
8%
ROCE
9%
ROIC
13%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 761.8B USD
ROE
66%
ROA
13%
ROCE
33%
ROIC
19%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country DK
Market Cap 3.3T DKK
ROE
89%
ROA
27%
ROCE
75%
ROIC
35%
Country US
Market Cap 368.4B USD
ROE
20%
ROA
8%
ROCE
18%
ROIC
13%
Country US
Market Cap 250.9B USD
ROE
28%
ROA
11%
ROCE
25%
ROIC
20%
Country CH
Market Cap 208.8B CHF
ROE
40%
ROA
13%
ROCE
29%
ROIC
22%
Country CH
Market Cap 181.2B CHF
ROE
35%
ROA
16%
ROCE
20%
ROIC
15%
Country UK
Market Cap 158.6B GBP
ROE
17%
ROA
6%
ROCE
14%
ROIC
12%
Country IE
Market Cap 155B USD
ROE
70%
ROA
-51%
ROCE
5%
ROIC
6%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top